TY - JOUR
T1 - Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC)
AU - Babiker, Hani M.
AU - Karass, Michael
AU - Recio-Boiles, Alejandro
AU - Chandana, Sreenivasa R.
AU - McBride, Ali
AU - Mahadevan, Daruka
N1 - Publisher Copyright:
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2019/7/3
Y1 - 2019/7/3
N2 - Introduction: PDAC is a lethal malignancy with a clear unmet need; almost all patients fail 1st, 2nd, and 3rd line multi-agent cytotoxic chemotherapy. The mammalian target of rapamycin (mTOR) has been identified as a key signaling node enhancing tumor survival and drug resistance in PDAC; hence, it is considered a promising therapeutic target. Areas covered: We comprehensively reviewed the evidence from preclinical and phase I and II clinical trials, based on the authors’clinical experience and a PubMed, Cochrane library, Embase, and Google Scholar search everolimus + pancreatic cancer. Expert opinion: Everolimus has not demonstrated efficacy in PDAC; however, an mTOR inhibitor in combination with stroma-targeted therapies may be a promising area to explore in clinical trials.
AB - Introduction: PDAC is a lethal malignancy with a clear unmet need; almost all patients fail 1st, 2nd, and 3rd line multi-agent cytotoxic chemotherapy. The mammalian target of rapamycin (mTOR) has been identified as a key signaling node enhancing tumor survival and drug resistance in PDAC; hence, it is considered a promising therapeutic target. Areas covered: We comprehensively reviewed the evidence from preclinical and phase I and II clinical trials, based on the authors’clinical experience and a PubMed, Cochrane library, Embase, and Google Scholar search everolimus + pancreatic cancer. Expert opinion: Everolimus has not demonstrated efficacy in PDAC; however, an mTOR inhibitor in combination with stroma-targeted therapies may be a promising area to explore in clinical trials.
KW - Everolimus
KW - mTOR
KW - pancreatic adenocarcinoma
UR - http://www.scopus.com/inward/record.url?scp=85067883671&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067883671&partnerID=8YFLogxK
U2 - 10.1080/13543784.2019.1632289
DO - 10.1080/13543784.2019.1632289
M3 - Article
C2 - 31215251
AN - SCOPUS:85067883671
SN - 1354-3784
VL - 28
SP - 583
EP - 592
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
IS - 7
ER -